Navigating AI risks in healthcare just got easier with the FDA's new draft guidance and explanations from Guillaume Gigon, Innovaderm's VP of Technology and AI.
You can even comment on the FDA draft document by April 7.
Newsletter
Table of contents Sessions on Vitiligo Sessions on Rheumatology Sessions on Nail Diseases Sessions on Hair Disorders Sessions on Aesthetic Sessions on Innovative Therapies Late-Breaking Research and News Conclusion The American Academy of Dermatology (AAD) Annual Meeting is just around the corner, and it promises to be an exciting event filled with the latest advancements […]
In the ever-evolving landscape of clinical research, Phase I studies are becoming increasingly complex. We’re proud to announce that two of our trailblazing colleagues, Ana Palijan, Director, Early Phase and Translational Research, and Éric Hardy, Senior Director, Biometrics, have contributed to a groundbreaking white paper that explores these complexities. Their expert analysis highlights the challenges […]
Contract Research Organizations (CRO) are the backbone of the clinical research industry, driving research and development that leads to new therapies and treatments. With a multitude of CROs in the market, each offering a unique set of services and expertise, identifying the frontrunners in dermatology CRO arena can be a daunting task. This challenge is […]
